BackSAB Biotherapeutics Overview

SAB Biotherapeutics Current Cash

SAB Biotherapeutics's current cash is $21M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$20.52M
↑ 263.80% YoYΔ $14.88M vs prior year quarter

Peer average

Loading

SAB Biotherapeutics Current Cash History

Loading

SAB Biotherapeutics vs. peers: Current Cash Comparison

Loading

SAB Biotherapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

SAB Biotherapeutics (SABS) FAQ

SAB Biotherapeutics posts a current cash of $21M as of March 2026. That compares with $5.6M in the prior-year period — up 263.8% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, SAB Biotherapeutics's current cash was $5.6M. The latest reading is $21M — a 263.8% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Current Cash is one piece of SAB Biotherapeutics's financial statement story. At $21M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for SABS's current cash usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; SAB Biotherapeutics's other metric pages and overview cover the third.